Unternehmen DiaMedica Therapeutics Inc. Toronto S.E.
Aktien
DMA
CA25253X2077
DMA
Biotechnologie
Kurzporträt
Mitarbeiterzahl: 19
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
Rick Pauls
CEO | Chief Executive Officer | 52 | 01.04.05 |
Scott Kellen
DFI | Director of Finance/CFO | 59 | 01.04.18 |
Ambarish Shah
CTO | Chief Tech/Sci/R&D Officer | - | 01.05.23 |
Chief Tech/Sci/R&D Officer | 62 | 22.01. | |
James Parsons
BRD | Director/Board Member | 58 | 20.10.10 |
Paul Papi
IRO | Public Communications Contact | - | 01.12.16 |
Corporate Officer/Principal | - | - | |
Dominic Cundari
PRN | Corporate Officer/Principal | - | 01.02.22 |
David Wambeke
PRN | Corporate Officer/Principal | - | 11.04.23 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Richard Kuntz
BRD | Director/Board Member | 66 | 30.05.23 |
Tanya Lewis
BRD | Director/Board Member | 53 | 01.03.23 |
James Parsons
BRD | Director/Board Member | 58 | 20.10.10 |
Michael Giuffre
BRD | Director/Board Member | 68 | 10.08.10 |
Rick Pauls
CEO | Chief Executive Officer | 52 | 01.04.05 |
Richard Pilnik
CHM | Chairman | 67 | 01.05.09 |
Charles Semba
BRD | Director/Board Member | 64 | 15.07.21 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 37 963 916 | 23 523 153 ( 61,96 %) | 0 | 61,96 % |
Unternehmenskontakt
DiaMedica Therapeutics, Inc.
301 Carlson Parkway Suite 210
55305, Minneapolis
+
http://www.diamedica.comSektor
% 1. Jan. | Kap. | |
---|---|---|
+8,29 % | 113 Mrd. | |
+10,21 % | 106 Mrd. | |
+0,41 % | 22,27 Mrd. | |
-11,90 % | 22,22 Mrd. | |
-5,99 % | 19,43 Mrd. | |
-37,36 % | 17,87 Mrd. | |
-5,17 % | 17,24 Mrd. | |
+7,70 % | 14,29 Mrd. | |
+37,65 % | 12,52 Mrd. |